President of @FightCRC. Passionate about community engagement, patient empowerment, and social good. #crcadvocacy #CancerSurvivor 💪🏽 #RelentlessChampions
Joined December 2011
- Tweets8.4K
- Following1.1K
- Followers1.9K
- Likes18.8K
AnjeeDavis retweeted
We're rallying 500 climbers across the country to show that #NoOneClimbsAlone.
So let's do this together.
You can join from anywhere:
✔️ Stairs
✔️ Trails
✔️ Treadmills
✔️ Neighborhood walks
Register for #ClimbForACure before July 1: fightcrc.org/climb
AnjeeDavis retweeted
Our #ClinicalTrials Newsletter delivers the latest #colorectalcancer updates, expert insights, & clinical trial highlights straight to your inbox—explore the information that matters most to you, all in one place 📫
Thank you to our sponsors 💙: @Merck @JNJNews @bmsnews @SMMT_TX
AnjeeDavis retweeted
Turn your story into action. 📣 Join our upcoming Advocacy Action Hour on July 16 at 8:30 PM ET to learn how to work with local media, write a media pitch, and amplify your advocacy beyond social media.
Register now: fightcrc.org/actionhr
AnjeeDavis retweeted
500 climbers needed nationwide by July 1.
Join #climbforacure from anywhere:
💪 Free to join
💪 No travel required
💪 Climb your way
💪 Raise $250 for research
Stairs. Hills. Trails. Treadmills. Your climb counts.
fightcrc.org/climb
AnjeeDavis retweeted
Tomorrow at 1 PM ET: Fight CRC's Research Highlights from @ASCO webinar.
Join @ChrisCannMD of @FoxChaseCancer & @ARosen380 for a discussion of promising #clinicaltrial results, advances in precision medicine, & emerging #CRC research.
Register now: fightcrc.org/webinars
AnjeeDavis retweeted
New research. New possibilities. 💪
We've rounded up the most important #colorectalcancer findings from #ASCO2026 and what they could mean for patients, survivors, and caregivers.
Read the recap: fightcolorectalcancer.org/as…
@ASCO
AnjeeDavis retweeted
Always great to listen to @KimmieNgMD She discussed the Coming Wave of Early-Onset Cancer. With it on the rise we need to do more for these patients. A dedicated program can help with coordination of supportive care service like fertility preservation! @ASCO #ASCO26 @FightCRC
AnjeeDavis retweeted
We need 500 climbers by July 1.
#Climbforacure is going nationwide, and you can join from anywhere.
Free to join. No travel required. Climb your way.
Register today: fightcrc.org/climb
AnjeeDavis retweeted
Come talk to me about patient-reported outcomes! See results of PROs in the ATOMIC A021502 trial - Atezolizumab+mFOLFOX6 vs mFOLFOX6 for adjuvant colon cancer. #ASCO26 @ALLIANCE_org
AnjeeDavis retweeted
We all need to do more to incorporate structured exercise program as an affordable & available option to #CRC patients. Thank you for all your work! @CDNCancerTrials Dr. Chris Booth @GillSharlene #ASCO26 #CHALLENGE #CRCSM
#ASCO26 @ASCO
Cost-utility analysis of #CHALLENGE trial of structured #exercise (SEP) after ACT for stage 2-3 colon cancer @CDNCancerTrials 🇨🇦
📌SEP improves DFS & OS
➡️ SEP is less costly & more effective ‘Win-Win’ ✅
‼️We need to implement SEP into routine care 💪 #NoExcuses
@JCO_ASCO
🔗 ascopubs.org/doi/10.1200/JCO…
AnjeeDavis retweeted
#ASCO26 Abs LBA #3508: EPISODE-III (JCOG 1503C) randomizes ONLY stage III #coloncancer pts to ASA 100 mg x 3 yrs vs. placebo post adjuvant chemo. Primary endpoint = DFS. #cancer #cancerresearch @OncoAlert
Differs vs. ALASCAA trial (Martling et al; NEJM, 2025)
EPISODE-III
👉Stage III colon
👉PIK3CA MT was not required (PIK3CA MT analysis is ongoing)
👉Adjuvant therapy was required
🛑 In unselected patients, ASA 100 mg was not beneficial for DFS
AnjeeDavis retweeted
Kicking off the day at @ASCO with a talk discussing the role of ctDNA across the spectrum of cancer care from early detection to treatment by Valsamo Anagnostou of @HopkinsKimmel!
#ASCO26 #FightCRCRats #cancer @OncoAlert
AnjeeDavis retweeted
🚨HOT TOPIC: Multicancer Early Detection: Potential Versus Proof results by Mark Robson MD @MSKCancerCenter.
As an advocate do I tell patients to ask for it based on these results? Thoughts are welcome! #CRCTwitter #GITwitter #ASCO26 #FightCRCRats
@ASCO @FightCRC @OncoAlert
AnjeeDavis retweeted
#ASCO26: LBA #3501- Optimal duration of #adjuvant #chemotherapy (ACT) in resected stage I-IV #colorectal #cancer: Galaxy Japan #ctDNA dynamics.
👉No benefit from continuing ACT if neg
👉 Also suggests no benefit to continue > 3M if neg
👉Rise in ctDNA at 3M suggests do NOT continue
👉For my practice, the role of #ctDNA dynamics will be CONSIDERED as an additional tool during ACT. @asco @OncoAlert
AnjeeDavis retweeted
Our #ASCO26: #BREAKWATER #PFS and #OS results with the FOLFIRI chemo backbone in #BRAFV600E MT #colorectalcancer.
👉PFS: Median 15.2 vs. 8.3M, HR = 0.44
👉 OS: Median NR vs. 20.3M, HR = 0.53
We are so glad to provide another option for our pts!
@PfizerOncMed @ASCO #cancer #cancerresearch @OncoAlert
AnjeeDavis retweeted
@theNCI #SWOG2107 #ASCO26 Phase II of encorafenib + cetuximab +/- nivo (CMS1) for #BRAFV600MT mCRC. Unfortunately could not validate PFS based on earlier @UTMDAnderson pilot findings. However, it reinforces creating a hypothesis and the need for validation! @VanMorrisMD #cancer #cancerresearch @OncoAlert
AnjeeDavis retweeted
#ABS #3502 #ASCO26: Observation vs. Maintenance #PD-1 therapy after clinical complete response (cCR) in dMMR/MSI-H managed with #NOM suggesting holding IO therapy at time of cCR does not negatively impact prognosis. @ASCO #cancerresearch @OncoAlert #cancer
AnjeeDavis retweeted
@ASCO #ASCO26 LBA 3500: DFS and TTR with ctDNA for adjuvant treatment in Stage II colon CA presented by Dr. Folprecht limited by:
👉Low ctDNA+ only 2.9%
👉 Created 10 yrs ago with limited 81 gene assay
👉 Closed early due to loss of funding
👉Remains prognostic for DFS and OS
@ASCO #cancerresearch #cancer @OncoAlert
AnjeeDavis retweeted
Flexing a #StrongArmSelfie at our Celebration of Queer Joy! 💪💙
We hope to see you there!
@ColonCancerCoal @HRC_Chicago
